Perspective Therapeutics, Inc. (CATX)
NYSEAMERICAN: CATX · Real-Time Price · USD
2.640
-0.090 (-3.30%)
Oct 30, 2025, 4:00 PM EDT - Market closed
Perspective Therapeutics Revenue
Perspective Therapeutics had revenue of $290.00K in the quarter ending June 30, 2025, a decrease of -44.87%. This brings the company's revenue in the last twelve months to $1.24M, down -15.64% year-over-year. In the year 2024, Perspective Therapeutics had annual revenue of $1.45M with 1.39% growth.
Revenue (ttm)
$1.24M
Revenue Growth
-15.64%
P/S Ratio
159.24
Revenue / Employee
$8,821
Employees
140
Market Cap
196.05M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 1.45M | 20.00K | 1.39% |
| Dec 31, 2023 | 1.43M | -3.98M | -73.52% |
| Dec 31, 2022 | 5.42M | - | - |
| Jun 30, 2022 | - | - | - |
| Jun 30, 2021 | 10.05M | 373.00K | 3.85% |
| Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| Eli Lilly and Company | 59.42B |
| AbbVie | 58.33B |
| AstraZeneca | 56.50B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.11B |
CATX News
- 6 days ago - Perspective Therapeutics to Provide Business Highlights and Report Third Quarter 2025 Financial Results - GlobeNewsWire
- 10 days ago - Perspective Therapeutics, Inc. (CATX) Discusses Updated Interim VMT-a-NET Clinical Data Presented at ESMO Transcript - Seeking Alpha
- 10 days ago - Perspective Therapeutics Presents Updated Interim Data from its Ongoing Phase 1/2a Clinical Trial of [212Pb]VMT-α-NET at the ESMO Congress 2025 - GlobeNewsWire
- 2 months ago - Perspective Therapeutics Appoints Maya Martinez-Davis to Board of Directors - GlobeNewsWire
- 2 months ago - Perspective Therapeutics to Participate in Upcoming September Conferences - GlobeNewsWire
- 2 months ago - Perspective Therapeutics Provides Recent Business Highlights and Reports 2Q 2025 Results - GlobeNewsWire
- 3 months ago - Perspective Therapeutics: Giving Us Some Valuable Perspective On Alpha Emitter Therapy - Seeking Alpha
- 3 months ago - Perspective Therapeutics Announces Acceptance of VMT-α-NET Data for Presentation at the ESMO Congress 2025 - GlobeNewsWire